Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.20
+$0.02 · +0.63%
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
Latest quote
$3.20
+$0.02 · +0.63%
After-hours
$3.20
$0.00 · 0.00%
Oct 8, 7:47 PM ET
Regular session · ET · Market data may be delayed.
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
Day range
Current $3.20
52-week range
Current $3.20
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
65
Undervalued
Sentiment
59
Mixed
Risk
85
Extreme Risk
Momentum
21
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
Day range
Current $3.20
52-week range
Current $3.20
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | — | 86K USD | 12K USD | — | 785.15K USD |
| Cost of goods sold | 240K USD | 246K USD | 103K USD | — | 6.34K USD |
| Gross profit | −240K USD | −160K USD | 12K USD | — | 778.79K USD |
| Research and development | 5.21M USD | 10.75M USD | 19.28M USD | 9.5M USD | 5.37M USD |
| Selling, general, and administrative | 17.82M USD | 13.13M USD | 25.56M USD | 11.93M USD | 10.18M USD |
| Operating expenses | 22.79M USD | 23.63M USD | 30.05M USD | 20.53M USD | 12.13M USD |
| Interest income | 21K USD | 62K USD | 308.4K USD | 362.73K USD | 6.27K USD |
| Interest expense | — | 303K USD | — | — | — |
| Depreciation and amortization | 240K USD | 246K USD | 103K USD | 132.45K USD | 11.35M USD |
| Operating income | −23.03M USD | −23.79M USD | −30.04M USD | −20.53M USD | −11.35M USD |
| Net income | −19.3M USD | −46.89M USD | −18.46M USD | −73.47M USD | −14.9M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
